JP2021531756A - CCR4を標的指向する改変Fc抗原結合ドメイン構築体に関する組成物および方法 - Google Patents

CCR4を標的指向する改変Fc抗原結合ドメイン構築体に関する組成物および方法 Download PDF

Info

Publication number
JP2021531756A
JP2021531756A JP2021500823A JP2021500823A JP2021531756A JP 2021531756 A JP2021531756 A JP 2021531756A JP 2021500823 A JP2021500823 A JP 2021500823A JP 2021500823 A JP2021500823 A JP 2021500823A JP 2021531756 A JP2021531756 A JP 2021531756A
Authority
JP
Japan
Prior art keywords
domain
polypeptide
monomer
domain monomer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531756A5 (cg-RX-API-DMAC7.html
Inventor
エルマ クルタギッチ
ローラ ルチツキ
ダニエル オルティス
ジョナサン シー. ランシング
アンソニー マニング
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2021531756A publication Critical patent/JP2021531756A/ja
Publication of JP2021531756A5 publication Critical patent/JP2021531756A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2021500823A 2018-07-11 2019-07-11 CCR4を標的指向する改変Fc抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021531756A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696746P 2018-07-11 2018-07-11
US62/696,746 2018-07-11
PCT/US2019/041324 WO2020014429A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4

Publications (2)

Publication Number Publication Date
JP2021531756A true JP2021531756A (ja) 2021-11-25
JP2021531756A5 JP2021531756A5 (cg-RX-API-DMAC7.html) 2022-07-20

Family

ID=69142497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500823A Withdrawn JP2021531756A (ja) 2018-07-11 2019-07-11 CCR4を標的指向する改変Fc抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20250346676A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820517A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021531756A (cg-RX-API-DMAC7.html)
KR (1) KR20210042324A (cg-RX-API-DMAC7.html)
CN (1) CN113164590A (cg-RX-API-DMAC7.html)
AU (1) AU2019302662A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000391A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105985A1 (cg-RX-API-DMAC7.html)
IL (1) IL279987A (cg-RX-API-DMAC7.html)
MX (1) MX2021000290A (cg-RX-API-DMAC7.html)
WO (1) WO2020014429A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250084169A1 (en) 2022-01-12 2025-03-13 Biomolecular Holdings Llc Nk/monocyte engagers
CN119233997A (zh) * 2022-01-12 2024-12-31 生物分子控股有限责任公司 四面体抗体
CN121100128A (zh) * 2023-04-24 2025-12-09 百图生科(苏州)智能科技有限公司 异源多聚体多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
WO2009086514A1 (en) * 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
AU2013256010B2 (en) * 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
US12391759B2 (en) * 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs

Also Published As

Publication number Publication date
AU2019302662A1 (en) 2021-02-25
CA3105985A1 (en) 2020-01-16
MX2021000290A (es) 2021-09-08
KR20210042324A (ko) 2021-04-19
IL279987A (en) 2021-03-01
EP3820517A2 (en) 2021-05-19
CN113164590A (zh) 2021-07-23
EP3820517A4 (en) 2022-04-06
WO2020014429A3 (en) 2020-02-13
US20250346676A1 (en) 2025-11-13
WO2020014429A2 (en) 2020-01-16
BR112021000391A2 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
JP7045333B6 (ja) 操作されたFcコンストラクトに関する組成物及び方法
JP2021532085A (ja) CTLA−4を標的とする改変されたFc抗原結合ドメイン構築体に関する組成物および方法
JP2021531268A (ja) 改変されたFc抗原結合ドメイン構築体に関する組成物および方法
JP2021530498A (ja) CD38を標的とする改変Fc抗原結合ドメイン構築体に関する組成物および方法
JP2021530992A (ja) 改変されたFc抗原結合ドメイン構築体に関する組成物および方法
US20250346676A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CCR4
JP2021530989A (ja) PD−L1を標的とした改変されたFc抗原結合ドメイン構築体に関する組成物および方法
JP2021531755A (ja) 改変されたFc−抗原結合ドメイン構築物に関する組成物および方法
JP2021531757A (ja) 改変されたFc−抗原結合ドメイン構築体に関する組成物および方法
KR20220119362A (ko) CD38을 표적으로 하는 조작된 Fc-항원 결합 도메인 작제물과 관련된 조성물 및 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210412

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210526

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220711

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220907